» Articles » PMID: 28761354

PD-1 Blockade Restores Impaired Function of Ex Vivo Expanded CD8 T Cells and Enhances Apoptosis in Mismatch Repair Deficient EpCAMPD-L1 Cancer Cells

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2017 Aug 2
PMID 28761354
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adoptive T cell therapy has been proven to be a promising modality for the treatment of cancer patients in recent years. However, the increased expression of inhibitory receptors could negatively regulate the function and persistence of transferred T cells which mediates T cell anergy, exhaustion, and tumor regression. In this study, we investigated increased cytotoxic activity after the blockade of PD-1 for effective immunotherapy.

Methods: The cytotoxic function of expanded CD8 CTLs and interactions with tumor cells investigated after blocking of PD-1. Ex vivo expanded CD8 CTLs were co-cultured with mismatch repair (MMR) stable or deficient (high microsatellite instability [MSI-H]) EpCAM tumor cells. The levels of IFN-γ and GrB were detected by enzyme-linked immunosorbent spot assay. Flow cytometry and confocal microscopy were used to assess CD107a mobilization, cytosolic uptake, and cell migration.

Results: A dramatic increase in PD-1 expression on the surface of CD8 CTLs during ex vivo expansion was observed. PD-1 level was downregulated by approximately 40% after incubation of the CD8 CTLs with monoclonal antibody which enhanced the secretion of IFN-γ, GrB, and CD107a. Additionally, PD-1 blockade enhanced cell migration and cytosolic exchange between CD8 CTLs and MMR deficient (MSI-H) EpCAMPD-L1 tumor cells.

Conclusion: The blockade of PD-1 enhanced the cytotoxic efficacy of CD8 CTLs toward MMR deficient tumor cells. In conclusion, we propose that blocking of PD-1 during the expansion of CD8 CTLs may improve the clinical efficacy of cell-based adoptive immunotherapy.

Citing Articles

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy.

Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F Mol Cancer. 2024; 23(1):9.

PMID: 38195537 PMC: 10775503. DOI: 10.1186/s12943-023-01925-5.


Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?.

Lee S, Lee S, Cho H, Min K, Hong J, Song J Int J Mol Sci. 2023; 24(2).

PMID: 36674491 PMC: 9865129. DOI: 10.3390/ijms24020974.


Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs.

Inanaga S, Igase M, Sakai Y, Hagimori K, Sunahara H, Horikirizono H J Vet Intern Med. 2022; 36(5):1760-1769.

PMID: 35959511 PMC: 9511092. DOI: 10.1111/jvim.16454.


Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.

Thibaudin M, Limagne E, Hampe L, Ballot E, Truntzer C, Ghiringhelli F Cancer Immunol Immunother. 2022; 71(10):2549-2563.

PMID: 35292828 PMC: 10992601. DOI: 10.1007/s00262-022-03182-9.


ANXA1 as a Prognostic and Immune Microenvironmental Marker for Gliomas Based on Transcriptomic Analysis and Experimental Validation.

Lin Z, Wen M, Yu E, Lin X, Wang H, Chen J Front Cell Dev Biol. 2021; 9:659080.

PMID: 34422796 PMC: 8371204. DOI: 10.3389/fcell.2021.659080.


References
1.
Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

2.
Melero I, Berman D, Aznar M, Korman A, Perez Gracia J, Haanen J . Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015; 15(8):457-72. DOI: 10.1038/nrc3973. View

3.
Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y . Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014; 110(10):2560-8. PMC: 4021514. DOI: 10.1038/bjc.2014.162. View

4.
Su S, Hu B, Shao J, Shen B, Du J, Du Y . CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016; 6:20070. PMC: 4730182. DOI: 10.1038/srep20070. View

5.
Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G . Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014; 110(6):1595-605. PMC: 3960618. DOI: 10.1038/bjc.2014.46. View